Veritas Pharma Inc. announced that it is working with its research arm, Cannevert Therapeutics Ltd. to design and implement the first clinical trials of cannabis strains targeting pain. Leading contract research organizations (CROs) with clinical experience of evaluating cannabis and pain are being considered for cost estimates and timelines. Veritas and Cannevert intend to implement these clinical trials in 2017 that meets the quality standards, i.e., Good Clinical Practices (GCPs). CROs with experience in evaluating cannabis for the treatment of pain are currently being visited and screened for suitability.